Semax belongs to a small group of peptides developed in Russia and studied far more extensively there than in Western literature. That geographic concentration is worth knowing about, because it shapes both what evidence exists and how accessible it is.
What Semax is
Semax is a synthetic heptapeptide based on the 4-10 fragment of adrenocorticotropic hormone (ACTH), with a proline-glycine-proline sequence added at the C-terminus. The parent ACTH fragment has well-documented effects on learning and memory in animal models but is rapidly degraded.
The added tripeptide tail is the engineering that makes the compound viable. It substantially slows enzymatic degradation, extending the peptide's half-life. Crucially, the ACTH(4-10) fragment itself lacks the hormonal activity of the full ACTH molecule, so Semax does not act as a corticotropic agent.
The neurotrophin mechanism
The most substantiated line of Semax research concerns brain-derived neurotrophic factor. Dolotov and colleagues published two complementary papers in 2006. The first, in the Journal of Neurochemistry, reported specific binding and increased BDNF protein levels in the rat basal forebrain.[1] The second, in Brain Research, examined regulation of BDNF and its receptor trkB in the rat hippocampus.[2]
Those two findings together are more informative than either alone. Demonstrating both ligand and receptor regulation in the same system is a stronger mechanistic claim than a change in one measured protein.
Speed of response
An earlier study in Neuroscience Letters reported rapid induction of neurotrophin messenger RNAs in rat glial cell cultures following Semax exposure.[3] Two details matter here. The response was fast, implying direct transcriptional action rather than a downstream cascade. And it occurred in glial cells rather than neurons, which points to glia as a target population that is often overlooked in neuropeptide work.
Behavioural models
A 2024 paper in the European Journal of Pharmacology examined antidepressant-like and antistress effects of Semax in male rats under chronic unpredictable stress, alongside melanotan II as a comparator.[4] Chronic stress paradigms are a more demanding test than acute designs, since they require the effect to persist.
Handling and stability
Semax is supplied as a lyophilised solid and stored at −20°C, protected from light and moisture. Reconstitution follows standard peptide practice: sterile solvent down the vial wall, gentle swirling, no vortexing.
The proline-glycine-proline tail that confers resistance to enzymatic degradation does nothing to protect against the physical degradation routes that affect all peptides in solution. Aggregation, surface adsorption and freeze-thaw damage apply as they would to any short peptide, and single-use aliquots remain the sensible approach.
What the literature does not establish
A large proportion of Semax research is published in Russian-language journals, and some is not indexed in the databases Western researchers search by default. This creates two problems: relevant work is easy to miss, and some of what exists has not been subject to the same replication scrutiny as more widely circulated literature.
Independent replication outside the original research groups remains limited. The BDNF findings are the best-supported element of the picture; broader claims rest on a thinner base than their frequent repetition online would suggest.
References
- Dolotov OV. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Journal of Neurochemistry. 2006. PMID 16635254
- Dolotov OV. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006. PMID 16996037
- Shadrina MI. Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog. Neuroscience Letters. 2001. PMID 11457573
- Inozemtseva LS. Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress. European Journal of Pharmacology. 2024. PMID 39442746
Research use only
Semax is supplied by MMpeptides strictly for laboratory and in vitro research. It is not approved for human or veterinary use, is not a cosmetic or medicinal product, and nothing in this article should be read as describing use in people. Third-party studies are cited for scientific context only. Researchers are responsible for observing all applicable regulations in their jurisdiction.